Ebola virus

Close up of vaccine syringe
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Outbreak

CEPI backs Minapharm’s Bundibugyo ebolavirus vaccine candidate

African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate.  The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More

#News #Trending News

Ebola outbreak
#CEPI #Ebola virus #Immunology / Virology & Vaccines #Moderna #Outbreak

Phase I trial “a major step forward” against Ebola outbreak

Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV).  “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More

#Editor's Choice #News #Trending News

Testing antiviral vaccines in the lab
#Antivirals #Covid-19 treatment #Ebola virus #Infectious diseases #Pneumonia #University of Queensland #Viral infections #Virus treatment

The lightbulb moment behind a potential antiviral breakthrough 

An unexpected observation by a University of Queensland (UQ) researcher could lead to a new treatment for deadly infectious diseases including Covid‑19, pneumonia in infants and children, or viral infections caused by Ebola and hantavirus.   UQ’s Australian Institute for Bioengineering and Nanotechnology neuroscientist and biochemist Dr… Read More

#News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Vaccine discovery
#Ebola virus #Immunology / Virology & Vaccines #Outbreak #University of Oxford

UK group steps up Ebolavirus vaccine development in response to outbreak

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) has reported that it is working urgently with the Clinical BioManufacturing Facility and the Serum Institute of India (SIIPL) to rapidly produce and scale doses of its ChAdOx-based monovalent… Read More

#News #Trending News

#Adaptvac #CEPI #Disease X #Ebola virus #Immunology / Virology & Vaccines #Pandemic prevention

All-in-one vaccine development backed by $12.4m funding

Scientists at Denmark’s Adaptvac will lead the development of a new vaccine that could provide all-in-one protection against multiple deadly viruses, including Ebolavirus Zaire, Sudan Ebolavirus and Marburg.  Backed by $12.4 million of funding from CEPI and the European Union’s Horizon Europe programme, a global consortium led… Read More

#Editor's Choice #News

Ebola virus
#Animal testing #Ebola virus #Immunology / Virology & Vaccines #National Institute of Allergy and Infectious Diseases #National Institutes of Health (NIH) #Vaccine candidate #Vaccines

Experimental vaccine protects against deadly Sudan virus

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine.   SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease. The new vaccine, VSV-SUDV, completely… Read More

#Editor's Choice #News